Gender Differences in the One-Year Outcomes of Prasugrel versus
Ticagrelor in Acute Myocardial Infarction Treated With Primary
Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

a 2018

Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

KALA, Petr, Zuzana MOTOVSKA, Ota HLINOMAZ, Milan HROMADKA, Jiří KNOT et. al.

Základní údaje

Originální název

Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study

Autoři

KALA, Petr (203 Česká republika, garant, domácí), Zuzana MOTOVSKA (203 Česká republika), Ota HLINOMAZ (203 Česká republika, domácí), Milan HROMADKA (203 Česká republika), Jiří KNOT (203 Česká republika), Ivo VARVAROVSKY (203 Česká republika), Jaroslav DUSEK (203 Česká republika), Roman MIKLIK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Stanislav SIMEK (203 Česká republika), Marian BRANNY (203 Česká republika), Jan MROZEK, Pavel CERVINKA (203 Česká republika), Jiri OSTRANSKY (203 Česká republika), Richard ROKYTA (203 Česká republika), Frantisek TOUSEK (203 Česká republika) a Petr WIDIMSKY (203 Česká republika)

Vydání

2018

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 23.054

Kód RIV

RIV/00216224:14110/18:00118136

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000528619406361

Klíčová slova anglicky

Acute Myocardial Infarction; Primary Angioplasty; Prasugrel; Ticagrelor

Příznaky

Mezinárodní význam

Změněno: 9. 2. 2021 07:44, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Prasugrel and ticagrelor have shown similar primary net-clinical endpoint (cardiovascular death, spontaneous MI, stroke, severe bleeding or revascularization at day 7) and similar clinical effectivity in the PRAGUE-18 study at one year. Hypothesis: Impact of gender on the clinical outcome up to 12 months. Methods: A total of 1,230 patients with acute MI (931 males; 75.7%) treated with primary PCI were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. Key secondary efficacy endpoint (EP) was cardiovascular death, spontaneous MI, stroke within 30 days and at one year. Results: Females were older (64.9 vs 60.9 years; p<0.001), more often hypertensive (63.2% vs 47.4%; p<0.001) and diabetics (27.8% vs 17.9%; p<0.001) and there were less smokers (58.9% vs 66.8%; p=0.015). Females suffered significantly longer time interval from symptom onset to the admission to PCI center (3.3hrs vs 2.5hrs; p=0.001). In females, the primary net-clinical EP at 7 days was not different from males (4.4% vs 3.9%; p=0.645) but at 30 days, the rate of MI and combined key efficacy EP occurred significantly more often(5.4% vs 2.7%; p=0.030 [HR 5.234; 95% CI, 1.902-14.401] and 3.3% vs 0.6%; p=0.001 [HR 2.007 95% CI, 1.072-3.759], respectively). At 12 months, there was no significant difference between the groups, though a strong trend to higher rate of MI and bleeding was found (HR 1.968, 95% CI 0.985-3.929; p=0.055 and HR 1.399 95% CI 0.970-2.020; p=0.073, respectively). End of potent P2Y12 treatment within one year was observed more often in females than males, though not statistically significant (58.5% vs 52.0%; p=0.053). No significant difference was found in the economically driven switch to clopidogrel (43.1% vs 37.8%; p=0.103). Conclusions: In the PRAGUE-18 study, the female patients were at higher baseline clinical risk, had significantly higher rate of MI and cardiovascular death/MI/stroke at 30 days and tended to have a higher rate of repeated MI and bleeding complications at 12 months. Longer pre-hospital ischemic time in females requires special attention.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Citovat

KALA, Petr, Zuzana MOTOVSKA, Ota HLINOMAZ, Milan HROMADKA, Jiří KNOT, Ivo VARVAROVSKY, Jaroslav DUSEK, Roman MIKLIK, Jiří JARKOVSKÝ, Stanislav SIMEK, Marian BRANNY, Jan MROZEK, Pavel CERVINKA, Jiri OSTRANSKY, Richard ROKYTA, Frantisek TOUSEK a Petr WIDIMSKY. Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study. 2018. ISSN 0009-7322.

@proceedings{1739836,
   author = {Kala, Petr and Motovska, Zuzana and Hlinomaz, Ota and Hromadka, Milan and Knot, Jiří and Varvarovsky, Ivo and Dusek, Jaroslav and Miklik, Roman and Jarkovský, Jiří and Simek, Stanislav and Branny, Marian and Mrozek, Jan and Cervinka, Pavel and Ostransky, Jiri and Rokyta, Richard and Tousek, Frantisek and Widimsky, Petr},
   keywords = {Acute Myocardial Infarction; Primary Angioplasty; Prasugrel; Ticagrelor},
   language = {eng},
   title = {Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study},
   url = {https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557},
   year = {2018}
}

TY  - CONF
ID  - 1739836
AU  - Kala, Petr - Motovska, Zuzana - Hlinomaz, Ota - Hromadka, Milan - Knot, Jiří - Varvarovsky, Ivo - Dusek, Jaroslav - Miklik, Roman - Jarkovský, Jiří - Simek, Stanislav - Branny, Marian - Mrozek, Jan - Cervinka, Pavel - Ostransky, Jiri - Rokyta, Richard - Tousek, Frantisek - Widimsky, Petr
PY  - 2018
TI  - Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study
KW  - Acute Myocardial Infarction
KW  - Primary Angioplasty
KW  - Prasugrel
KW  - Ticagrelor
UR  - https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557
L2  - https://www.ahajournals.org/doi/10.1161/circ.138.suppl_1.16557
N2  - Introduction: Prasugrel and ticagrelor have shown similar primary net-clinical endpoint (cardiovascular death, spontaneous MI, stroke, severe bleeding or revascularization at day 7) and similar clinical effectivity in the PRAGUE-18 study at one year. Hypothesis: Impact of gender on the clinical outcome up to 12 months. Methods: A total of 1,230 patients with acute MI (931 males; 75.7%) treated with primary PCI were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. Key secondary efficacy endpoint (EP) was cardiovascular death, spontaneous MI, stroke within 30 days and at one year. Results: Females were older (64.9 vs 60.9 years; p<0.001), more often hypertensive (63.2% vs 47.4%; p<0.001) and diabetics (27.8% vs 17.9%; p<0.001) and there were less smokers (58.9% vs 66.8%; p=0.015). Females suffered significantly longer time interval from symptom onset to the admission to PCI center (3.3hrs vs 2.5hrs; p=0.001). In females, the primary net-clinical EP at 7 days was not different from males (4.4% vs 3.9%; p=0.645) but at 30 days, the rate of MI and combined key efficacy EP occurred significantly more often(5.4% vs 2.7%; p=0.030 [HR 5.234; 95% CI, 1.902-14.401] and 3.3% vs 0.6%; p=0.001 [HR 2.007 95% CI, 1.072-3.759], respectively). At 12 months, there was no significant difference between the groups, though a strong trend to higher rate of MI and bleeding was found (HR 1.968, 95% CI 0.985-3.929; p=0.055 and HR 1.399 95% CI 0.970-2.020; p=0.073, respectively). End of potent P2Y12 treatment within one year was observed more often in females than males, though not statistically significant (58.5% vs 52.0%; p=0.053). No significant difference was found in the economically driven switch to clopidogrel (43.1% vs 37.8%; p=0.103). Conclusions: In the PRAGUE-18 study, the female patients were at higher baseline clinical risk, had significantly higher rate of MI and cardiovascular death/MI/stroke at 30 days and tended to have a higher rate of repeated MI and bleeding complications at 12 months. Longer pre-hospital ischemic time in females requires special attention.
ER  -

KALA, Petr, Zuzana MOTOVSKA, Ota HLINOMAZ, Milan HROMADKA, Jiří KNOT, Ivo VARVAROVSKY, Jaroslav DUSEK, Roman MIKLIK, Jiří JARKOVSKÝ, Stanislav SIMEK, Marian BRANNY, Jan MROZEK, Pavel CERVINKA, Jiri OSTRANSKY, Richard ROKYTA, Frantisek TOUSEK a Petr WIDIMSKY. \textit{Gender Differences in the One-Year Outcomes of Prasugrel versus Ticagrelor in Acute Myocardial Infarction Treated With Primary Angioplasty: A Posthoc Analysis of the PRAGUE-18 Study}. 2018. ISSN~0009-7322.

Podrobný výpis o publikaci